Previous studies have identified biomarkers such as 1p/19q codeletion [49], isocitrate dehydrogenase [50], EGFR [51], and O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation [52] as indicators for gliomas. This evidence concerns the gene MGMT and central nervous system cancer.